Aurinia Pharmaceuticals (AUPH) EBT (2019 - 2026)

Aurinia Pharmaceuticals has reported EBT for 8 years, with the latest figure at $43.9 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 80.4% year-over-year to $43.9 million; the trailing twelve-month figure through Mar 2026 stood at $133.7 million (up 219.88% YoY), and the FY2025 full-year result was $114.2 million, up 1432.72% from the prior year.
• EBT for Q1 2026 stood at $43.9 million, up from $35.7 million in the prior quarter.
• The five-year high for EBT was $43.9 million in Q1 2026, with the low at -$37.6 million in Q1 2022.
• Historically, EBT has averaged -$1.1 million across 5 years, with a median of -$8.0 million in 2022.
• Annual changes were most pronounced in 2023 — EBT sank 63.65% — and 2025, when it soared 2942.63%.
• Aurinia Pharmaceuticals' EBT stood at -$25.2 million in 2022, then fell by 4.86% to -$26.4 million in 2023, then surged by 104.44% to $1.2 million in 2024, then soared by 2942.63% to $35.7 million in 2025, then rose by 23.07% to $43.9 million in 2026.
• The last three EBT figures came in at $43.9 million (Q1 2026), $35.7 million (Q4 2025), and $32.0 million (Q3 2025), per Business Quant data.